OctoPlus Signs Service Contract with Galapagos
News Feb 16, 2009
OctoPlus N.V. has announced that it has signed a pharmaceutical development contract with a new client, Galapagos N.V. The undisclosed contract value significantly contributes to OctoPlus' annual revenues.
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos' Phase II study of Nanocort®, a liposome formulation of prednisolone. OctoPlus has progressed the scale-up of the production process of this complex liposomal product.
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019